- Letter of Intent to acquire Agro-Biotech, to become vertically integrated from “seed to derivatives”
- Development and commercialization of therapeutic pharmaceuticals and nutraceuticals
- Patented formulation and delivery technologies
Scientific studies have provided empirical credence to the medical efficacy of cannabinoids for multiple maladies. Globally, researchers and biopharmaceutical companies are now laser focused on cannabinoid-based therapeutics that may hold blockbuster medical potential, providing solutions to a range of unmet medical needs. However, current drug delivery techniques remain antiquated. There are inherent metabolic and bioavailability issues affecting the consistent, effective delivery of cannabinoids. It’s becoming clear that these new pharmaceutical therapeutics require revolutionary delivery techniques. Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is establishing new paradigms in cannabinoid drug development and delivery.
Pivot Pharmaceuticals is transforming the development and commercialization of these new therapeutic pharmaceuticals and nutraceuticals with unique drug delivery platform technologies. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals, and it has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical) and Solmic Solubilisation technology (oral) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. The company recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office (http://ibn.fm/6Oi4A), and these latest patent filings join an established number of global rights to topical, oral, transdermal, food and beverage technologies that Pivot has already secured.
Pivot’s pipeline of potential CBD-based pharmaceuticals now covers treatment indications for supportive care to relieve nausea, mucositis and pain, including cancer-related and menstrual pain, dermatological conditions and even glaucoma. Pivot is also developing and commercializing an array of pharmaceutical-grade formulations for cannabinoid-based consumer health care products.
With enhanced drug delivery and development well underway, Pivot has turned to its next business objective, vertical integration. The company just announced a Letter of Intent for the proposed acquisition of Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://ibn.fm/ERNrg). Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility capable of producing a cumulative 10,000 kilograms per year.
Pivot is already a differentiated player in the Canadian cannabis industry due to its unique approach to enhanced dosing and bioavailability of cannabinoids with proven pharmaceutical and patented formulation and delivery systems. With the acquisition of Agro-Biotech, Pivot Pharmaceuticals expects to become vertically integrated, controlling the entire manufacturing process from “seed to derivatives” and capturing margin along the entire supply chain.
In the news release, Dr. Patrick Frankham, Pivot CEO, stated, “I am delighted to welcome Agro-Biotech to Pivot… With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization. Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are underway. After several months of identifying and discussing with potential partners in the cannabis space, the Pivot management team and our scientific advisors agreed that it was in the best interest of our shareholders to acquire the compliment of licenses which will enable us to develop our pipeline of patented formulation and delivery technologies all under one vertically integrated process from seed to derivatives. Pivot will only work with partners who truly control their processes and have the finest infrastructure and qualified personnel. We believe that these characteristics will define best in class products for wellness and health conscious consumers using bio-cannabis….”
This latest announcement follows a pattern of strong corporate development by Pivot Pharmaceuticals and uniquely positons the company to become a major force in the burgeoning cannabis markets not only in Canada but around the world.
For more information, visit the company’s website at www.PivotPharma.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
